Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Celldex Therapeutics (CLDX) Change in Accured Expenses (2016 - 2025)

Celldex Therapeutics has reported Change in Accured Expenses over the past 16 years, most recently at $4.6 million for Q4 2025.

  • Quarterly results put Change in Accured Expenses at $4.6 million for Q4 2025, down 71.99% from a year ago — trailing twelve months through Dec 2025 was $11.0 million (down 5.18% YoY), and the annual figure for FY2025 was $11.0 million, down 5.18%.
  • Change in Accured Expenses for Q4 2025 was $4.6 million at Celldex Therapeutics, down from $13.1 million in the prior quarter.
  • Over the last five years, Change in Accured Expenses for CLDX hit a ceiling of $16.4 million in Q4 2024 and a floor of -$8.7 million in Q1 2025.
  • Median Change in Accured Expenses over the past 5 years was -$204500.0 (2021), compared with a mean of $1.5 million.
  • Biggest five-year swings in Change in Accured Expenses: tumbled 508.94% in 2021 and later soared 3147.24% in 2022.
  • Celldex Therapeutics' Change in Accured Expenses stood at -$550000.0 in 2021, then rose by 2.55% to -$536000.0 in 2022, then soared by 823.32% to $3.9 million in 2023, then skyrocketed by 323.68% to $16.4 million in 2024, then crashed by 71.99% to $4.6 million in 2025.
  • The last three reported values for Change in Accured Expenses were $4.6 million (Q4 2025), $13.1 million (Q3 2025), and $2.1 million (Q2 2025) per Business Quant data.